

Oncology Drug Development Report 2024

Immunotherapy and Targeted Therapy Analysis

The oncology market continues to be the fastest-growing therapeutic segment with breakthrough innovations in immuno-oncology and precision medicine.

Key Drug Classes:

- PD-1/PD-L1 Inhibitors: Market leader at USD 45B
- CAR-T Cell Therapies: Rapid growth, 6 approved products
- ADCs: 12 approved drugs, 100+ in development
- Bispecific Antibodies: Emerging class with 8 approvals

Clinical Pipeline Highlights:

- 2,400+ oncology trials in Phase 2/3
- NSCLC remains most active indication
- Combination therapies dominate new trials
- Biomarker-driven trials increased 60%

Market Outlook:

Global oncology market projected to reach USD 380B by 2028